DeepMed Research

Rasagiline

Generic Name: Rasagiline

Brand Names: Azilect, Rasagiline Mylan, Rasagiline ratiopharm

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₃N

CAS Number: 136236-51-6

Unique Ingredient Identifier: 003N66TS6T

Background: Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.

Indication: For the treatment of the signs and symptoms of idiopathic Parkinsons disease as initial monotherapy and as adjunct therapy to levodopa.

Associated Conditions: Parkinson's Disease (PD)

Clinical Trials

Tapering Heart Failure Medication in Patients with Heart Failure with Recovered Ejection Fraction; Open Label Prospective Random Trial

Not Applicable

Not yet recruiting

Conditions: Heart Failure
Ejection Fraction
Recovery of Function

Interventions: Drug: RAS blocker tapering group
Drug: Beta blocker tapering out

First Posted Date: 2024-12-09

Last Posted Date: 2024-12-09

Lead Sponsor: Chungnam National University Hospital

Target Recruit Count: 150

Registration Number: NCT06724653

Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN

Completed

Conditions: Primary IgA Nephropathy

Interventions: Drug: TARPEYO 4 MG Delayed Release Oral Capsule
Drug: RAS inhibitor

First Posted Date: 2024-09-10

Last Posted Date: 2024-09-10

Lead Sponsor: Ruijin Hospital

Target Recruit Count: 200

Registration Number: NCT06589752

Locations: 🇨🇳
Ruijin hospital, Shanghai, China

Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy

Completed

Conditions: Finerenone
IgA Nephropathy
Proteinuria
Safety Issues

Interventions: Drug: Finerenone
Drug: RAS inhibitor
Drug: Immune Suppressant

First Posted Date: 2024-06-14

Last Posted Date: 2024-06-14

Lead Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Target Recruit Count: 245

Registration Number: NCT06460987

Locations: 🇨🇳
Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy, Yiwu, Zhejiang, China

Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

Not Applicable

Recruiting

Conditions: Obesity
Chronic Kidney Diseases

Interventions: Drug: RAS inhibitors：Losartan®️/Valsartan®️
Drug: dapagliflozin：Forxiga®️
Drug: simagliptin：Forxiga®️

First Posted Date: 2024-04-03

Last Posted Date: 2024-04-03

Lead Sponsor: RenJi Hospital

Target Recruit Count: 48

Registration Number: NCT06344247

Locations: 🇨🇳
Renji Hospital Affiliated to Shanghai JIAO TONG University school of medicine, Shanghai, Shanghai, China

Long-term Use of CCB and Breast Cancer Risk

Active, not recruiting

Conditions: Hypertension,Essential
Breast Cancer

Interventions: Drug: Calcium channel blocker
Drug: Beta blocker
Drug: None AHT
Drug: Diuretic
Drug: RAS
Drug: Other AHT

First Posted Date: 2023-08-02

Last Posted Date: 2024-08-21

Lead Sponsor: Curtin University

Target Recruit Count: 68500

Registration Number: NCT05972785

Locations: 🇦🇺
Curtin university, Bentley, Western Australia, Australia

Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease

Phase 2

Withdrawn

Conditions: Synucleinopathies
REM Sleep Behavior Disorder
Parkinson Disease

Interventions: Drug: Rasagiline

First Posted Date: 2022-11-10

Last Posted Date: 2025-01-07

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 732

Registration Number: NCT05611372

GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)

Phase 4

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: GLP-1 RAs
Other: calorie restricted diet

First Posted Date: 2021-05-06

Last Posted Date: 2022-08-04

Lead Sponsor: Shanghai 10th People's Hospital

Target Recruit Count: 68

Registration Number: NCT04876027

Locations: 🇨🇳
Shanghai Tenth People' Hospital, Shanghai, Shanghai, China

The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value

Phase 4

Conditions: Peritoneal Dialysis Complication
Heart Failure
Hemodialysis Complication

Interventions: Drug: RAS Inhibitors
Drug: Sacubitril / Valsartan Oral Tablet

First Posted Date: 2020-10-01

Last Posted Date: 2020-10-08

Lead Sponsor: Shenzhen Second People's Hospital

Target Recruit Count: 120

Registration Number: NCT04572724

Locations: 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China

Rituximab and RASi in Patients with IgAN

Phase 4

Completed

Conditions: IgA Nephropathy

Interventions: Drug: Rituximab
Drug: RAS 2410

First Posted Date: 2020-08-25

Last Posted Date: 2025-03-14

Lead Sponsor: Nan Chen,MD

Target Recruit Count: 116

Registration Number: NCT04525729

Locations: 🇨🇳
Ruijin Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China

Rasagiline Tablets Special Drug Use-Results Survey "Survey on Long-term Safety"

Completed

Conditions: Parkinson's Disease

Interventions: Drug: Rasagiline

First Posted Date: 2018-11-01

Last Posted Date: 2024-03-08

Lead Sponsor: Takeda

Target Recruit Count: 1021

Registration Number: NCT03727139

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy